Related Experiment Video
Updated: Jun 10, 2026

Coral Reef Arks: An In Situ Mesocosm and Toolkit for Assembling Reef Communities
Published on: January 6, 2023
The ARUBA trial: current status, future hopes
J P Mohr1, Alan J Moskowitz, Christian Stapf
1Columbia University College of Physicians and Surgeons, Neurological Institute, New York, NY 10032-2603, USA. jpm10@columbia.edu
The Angiographic Arteriovenous Malformation (ARUBA) trial is progressing well, nearing patient enrollment goals. This National Institutes of Neurological Disorders and Stroke (NINDS)-supported study evaluates unbled brain arteriovenous malformations management.
Area of Science:
- Neurology
- Neurosurgery
- Clinical Trials
Background:
- Unbled brain arteriovenous malformations (AVMs) pose a significant risk of hemorrhage.
- Current management strategies for unbled AVMs involve observation or intervention.
Purpose of the Study:
- To report on the status of an ongoing clinical trial investigating the management of unbled brain arteriovenous malformations.
- To assess the efficacy and safety of intervention versus observation for unbled AVMs.
Main Methods:
- The trial is supported by the National Institutes of Neurological Disorders and Stroke (NINDS).
- The study began in April 2007 and has expanded to 65 centers.
- Patient randomization is ongoing, with 124 patients enrolled by mid-June 2010 towards a goal of 400.
Main Results:
- The trial is steadily approaching its monthly patient randomization targets.
- The current enrollment number is sufficient to compare intervention complication rates with natural history hemorrhage rates.
Conclusions:
- The Angiographic Arteriovenous Malformation (ARUBA) trial is on track for successful completion.
- The ongoing data collection will provide crucial insights into the optimal management of unbled brain AVMs.
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Trial and Error and Algorithm
Treatment Resistent Cancers
Robbers Cave
Treatment Resistant Cancers
